Go to Client Portal
NAMSA
Corie Diaz

Corie Diaz, BA, MBA

Global Director, Clinical Operations

Reserve your Consultation with our Experts

Contact Us

Corie Diaz has been in the industry for over 20 years with over 15 years focused on medical devices, primarily within the cardiovascular space

Corie has extensive experience in the management of clinical trials in North America, Europe and Asia-Pacific. In addition to leading Clinical Study Management, Site Management and Monitoring activities at NAMSA, Corie provides oversight of clinical research processes and delivery of services Clients. Her expertise encompasses all facets of research from trial design to execution, from studies of varying sizes and complexities within the medical device and pharmaceutical industries.

Corie has worked on both the CRO (Contract Research Organization) and Sponsor side, at both big and small companies, which enables her to understand all clinical stakeholder need.

Corie graduated with a Bachelor of Arts in Biological Sciences and a Master of Business Administration from Rutgers University.

CORE COMPETENCIES

  • Providing leadership and management direction to the Clinical Operations Team
  • Building effective working relationships with both internal and external partners
  • Managing clinical research activities, including development of clinical study conduct strategy, clinical trial execution, data coordination, reporting and the communication of results
  • Ensuring clinical studies are conducted according to applicable regulations and procedures with a high ethical/quality of standards; this allows clinical trial documentation to be in audit-ready condition
  • Overseeing clinical study execution to ensure studies are completed on time, within budget and in compliance with SOPs, ICH/GCP guidelines and applicable regulations
  • Assisting with the submission and review of all clinical deliverables required for regulatory submission

RECENT PROJECTS 

  • Enrolled a global pivotal coronary study with 1,200 subjects in six (6) months—one month ahead of schedule
  • Enrolled the first patient into a pivotal peripheral study within one (1) month of receiving IDE approval